Hammersmith Hospital
London, United Kingdom
20 recruiting
Showing 1–20 of 20 trials
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled399 locationsNCT06531824
Recruiting
Phase 2
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Pulmonary Hypertension
Pfizer36 enrolled36 locationsNCT07073820
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Prospective Evaluation of AI-ECG for SHD Detection
Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)Pulmonary Hypertension (Diagnosis)+1 more
Imperial College London590 enrolled5 locationsNCT07057466
Recruiting
Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals410 enrolled159 locationsNCT05730036
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Pfizer252 enrolled125 locationsNCT06977581
Recruiting
Phase 2
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Refractory Multiple MyelomaRelapse Multiple Myeloma
Janssen Research & Development, LLC130 enrolled38 locationsNCT06500884
Recruiting
Phase 1
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Acute Myeloid Leukemias
Syndax Pharmaceuticals76 enrolled46 locationsNCT06226571
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 3
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
End Stage Renal Disease
Iperboreal Pharma Srl170 enrolled41 locationsNCT03994471
Recruiting
Phase 2
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
University College, London60 enrolled11 locationsNCT05185739
Recruiting
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
Unresectable Hepatocellular Carcinoma (HCC)Liver Metastases From Colorectal Cancer (mCRC)
Sirtex Medical845 enrolled9 locationsNCT05967143
Recruiting
Phase 2Phase 3
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Pancreatic Ductal AdenocarcinomaPancreatic Cancer Stage IVPancreatic Cancer Metastatic
Panbela Therapeutics, Inc.600 enrolled93 locationsNCT05254171
Recruiting
Not Applicable
Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades
Heart FailurePacing-Induced Cardiomyopathy
Imperial College London155 enrolled12 locationsNCT06052475
Recruiting
Not Applicable
Ablation of Focal Activation in Atrial Fibrillation
Atrial FibrillationArrhythmias, CardiacArrhythmia+2 more
Imperial College London110 enrolled1 locationNCT06402617
Recruiting
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
NeoplasmsNeoplasms by SitePancreatic Neoplasm+5 more
OncoSil Medical Limited500 enrolled9 locationsNCT04493632
Recruiting
Not Applicable
HIS Alternative II - UK Site
Heart FailureLeft Bundle-Branch Block
Imperial College Healthcare NHS Trust40 enrolled1 locationNCT05814263
Recruiting
Not Applicable
The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF
Atrial FibrillationCardiac Arrhythmia
Imperial College London116 enrolled1 locationNCT05539040